Real World Evidence Comparison of First-Line (1L) Immune-Oncology(io)/tyrosine Kinase Inhibitor (TKI) Vs. IO/IO Combination Therapy in Renal Cell Carcinoma (RCC).
Journal of Clinical Oncology（2024）
Key words
283-424-3231-2482,283-424-3231,298-3438-2370-2813-7645,298-3438-2370-7650-2700,11890-11938,130-540-543-4790,298-3438-11609,3581,319,137,1880,1854
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined